Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.

Diagnostic pathology - 6 Feb 2013

Sundov Dinka, Caric Ana, Mrklic Ivana, Gugic Dijana, Capkun Vesna, Hofman Irena Drmic, Mise Branka Petric, Tomic Snjezana

Abstract excerpt

BACKGROUND: We investigated the immunohistochemical expression of p53, MAPK, topoisomerase II alpha (topoII alpha) and Ki67 in ovarian serous carcinomas (OSCs) along with mutational analysis for KRAS and BRAF. METHODS: Eighty one cases of OSCs were reviewed and examined immunohistochemically using antibodies against p53, MAPK, topoII alpha and Ki67. Staining was evaluated as a percentage of immunopositive cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Topoisomerases, Type II

Share to Ki-67 Antigen

Share to Microdissection

Share to Mitogen-Activated Protein Kinases

Share to Neoplasm Grading

Share to Neoplasms, Cystic, Mucinous, and Serous

Source

Open in PubMed Open full text

Identifiers

PMID: 23388101
DOI: 10.1186/1746-1596-8-21
PMCID: PMC3570323

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.PMID 23388101Read ↗

Low-grade serous ovarian cancer: A review.Semantic proximity Read ↗

Molecular characterization of 103 ovarian serous and mucinous tumors.Semantic proximity Read ↗

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.Semantic proximity Read ↗

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.Semantic proximity Read ↗

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.Semantic proximity Read ↗

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.Semantic proximity Read ↗

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.Semantic proximity Read ↗

Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.Semantic proximity Read ↗

[Molecular carcinogenesis of ovarian carcinoma].Semantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.Semantic proximity Read ↗

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.